Evidence map›Paper›PMID 41684577›Full record

ArticleArchives of medical science : AMS2025

CALCOCO2 silencing represents a potential molecular therapeutic target for glioma.

Zhisen Tian, Cong Ning, Changfeng Fu, Feng Xu, Congcong Zou, Qingsan Zhu, Jun Cai, Yuanyi Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhisen TianDepartment of Orthopaedics, China-Japan Union Hospital of Jilin University, Changchun, China.
Cong NingDepartment of Spine Surgery, The First Hospital of Jilin University, Changchun, China.
Changfeng FuDepartment of Spine Surgery, The First Hospital of Jilin University, Changchun, China.
Feng XuDepartment of Spine Surgery, The First Hospital of Jilin University, Changchun, China.
Congcong ZouDepartment of Spine Surgery, The First Hospital of Jilin University, Changchun, China.
Qingsan ZhuDepartment of Orthopaedics, China-Japan Union Hospital of Jilin University, Changchun, China.
Jun CaiPaediatric Research Institute, Department of Paediatrics, University of Louisville School of Medicine, Louisville, KY, USA.
Yuanyi WangDepartment of Spine Surgery, The First Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Glioma is the most common primary intracranial tumour that is highly resistant to conventional therapeutic approaches including surgical resection, radiation therapy, and chemotherapy. As a promising alternative treatment, gene therapy has achieved variable degrees in both pre-clinical models and clinical trials. Material and methods: In our present research, the role of calcium binding and coiled-coil domain 2 (CALCOCO2) in the pathogenesis and progression of glioma was investigated in human glioma U87 and U251 cell lines. In both cell lines, Results: Flow cytometry (FCM) and caspase3/7 measurements indicated that the silencing of Conclusions: The CALCOCO2 could be a potential target for glioma genetic therapy.

Indexed as

autophagygene silencinggliomamolecular mechanisms

Identifiers

PMID41684577
PMCPMC12892273

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.